Save 20% on your order with code
K4 Elite logo K4 Elite
Home / Peptide Library / Teriparatide
FDA Approved

Teriparatide

Hormonal & Endocrine · PTH(1-34), rhPTH(1-34), Forteo, Forsteo

A recombinant peptide corresponding to the first 34 N-terminal residues of human parathyroid hormone, studied in models of bone remodeling and mineral metabolism.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Molecular Formula
C181H291N55O51S2
Molecular Weight
4117.72 g/mol
PubChem
CID 16133850 ↗
Research Level
FDA Approved
Browse the store →
Teriparatide chemical structure

Teriparatide is the 1-34 N-terminal fragment of human parathyroid hormone (PTH), produced recombinantly and corresponding to the biologically active region of the 84-residue native hormone. It received U.S. FDA approval under the trade name Forteo and is a widely studied anabolic agent in bone research.

Whereas continuous elevation of PTH is associated in the literature with net bone resorption, intermittent exposure to PTH(1-34) has been studied for an anabolic pattern favoring bone formation - a distinction that has made teriparatide a reference compound in skeletal research.

Teriparatide binds the PTH/PTHrP type 1 receptor (PTH1R), a class B GPCR on osteoblasts and renal tubular cells, activating Gas/cAMP/PKA signaling in study models. Investigators attribute its anabolic profile to intermittent receptor stimulation that favors osteoblast activity over osteoclast-mediated resorption.

Downstream research describes effects on osteoblast lifespan, RANKL/OPG signaling, and calcium and phosphate handling in the kidney.

  • Bone remodeling - studied as an anabolic modulator of osteoblast activity [1][2].
  • Fracture-endpoint research - investigated for vertebral and non-vertebral fracture outcomes [1].
  • Fracture-healing models - examined in preclinical allograft and osteoporosis-healing studies [2][3].
  • Mineral metabolism - characterized for calcium/phosphate handling in study reports.
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

In the Fracture Prevention Trial (Neer et al., 2001), investigators administered PTH(1-34) to postmenopausal women with osteoporosis and reported reductions in new vertebral fractures (~65%) and non-vertebral fragility fractures (~53%) relative to placebo over a median ~21 months [1].

In a canine massive femoral allograft model, researchers reported that high-dose rPTH(1-34) increased callus volume and enhanced radiographic healing at 8 weeks [3].

A systematic review of osteoporotic fracture-healing studies compiled reported outcomes across multiple teriparatide investigations [2].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

SermorelinNeutral
Both are GPCR-targeting peptides but act on unrelated receptors (PTH1R vs GHRH-R); no combined research basis.
CalcitoninNeutral
Studied within opposing arms of calcium/bone regulation; often discussed comparatively in bone literature.
BisphosphonatesCaution
Sequencing and co-use with antiresorptives is an area of active comparative study; effects are context-dependent in reports.
  1. Neer et al., Effect of PTH(1-34) on fractures and BMD, N Engl J Med 2001;344:1434-1441
  2. Teriparatide in osteoporotic fracture healing: systematic review, PMC5357614
  3. High-dose rPTH(1-34) in canine femoral allograft healing, PMC5636088
  4. Teriparatide, PubChem CID 16133850
How does teriparatide differ from full-length PTH?
It is the 1-34 N-terminal fragment, which the literature identifies as the biologically active region of the 84-residue hormone [4].
Why is intermittent versus continuous exposure emphasized in research?
Studies describe intermittent PTH1R stimulation with an anabolic (bone-forming) pattern, contrasting with resorptive effects associated with continuous elevation [1].
Is this product intended for human use?
No. This entry is for research and informational purposes only and is not dosing guidance or a therapeutic recommendation.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.